Better investing begins with better research.

7investing Stock Market Research

Being your own investor doesn’t mean you have to go it alone. Improve your investing insights with the stock market research of the 7investing lead advisors.

Our team dives deeper, going beyond the tickers and trends to provide you with the credible, actionable information you need to make the right moves and achieve your stock market investing goals. Read on to stay up to date with the latest 7investing research articles, podcasts, videos, and updates on your favorite companies.

  • A single illuminated loan approval terminal in a vast empty operations floor at night, rows of unoccupied desks receding into darkness
    August 25, 2026||4.5 min||||

    77% of Upstart’s Loans Are Approved Without a Human Ever Seeing Them

    Upstart approves 77% of loans with zero human involvement. CEO Paul Gu explains why that number, not loan volume, is the real asset.

  • A heavy bank vault door standing ajar by only a few inches in a marble lobby, warm light spilling through the narrow gap
    August 25, 2026||4.4 min||||

    Upstart Didn’t Get a Bank Charter. It Got a Very Polite Maybe.

    Upstart received conditional approval to form a national bank in July 2026. Conditional is doing a lot of work in that sentence.

  • A steep ascending walkway emerging from deep shadow toward a lit doorway, the lower steps still lost in darkness
    August 25, 2026||4.1 min||||

    Upstart’s Worst Number Improved 61 Points in One Quarter

    Upstart's secured products ran a negative 35% contribution margin in Q2 2026, up from negative 176%. Management expects breakeven by Q4.

  • An empty executive chair turned toward a wall of monitors displaying dense model output, warm lamplight on an otherwise dark floor
    August 25, 2026||4.4 min||||

    Upstart’s New CEO Built the Robot That Approves Your Loan. Now He Has to Sell It.

    Paul Gu co-founded Upstart in 2012 and ran its technology. In May 2026 he became CEO. What changes when the model-builder runs the company?

  • A soap bubble and a baseball diamond rendered as overlapping translucent forms against a dark background
    August 21, 2026||8.7 min||||

    Is AI Spending a Bubble or the Early Innings? The Poll Came Back a Hung Jury

    Simon Erickson asked investors whether the AI build-out is early innings or a bubble about to pop. The split answer says something useful about how to position for either.

  • A suspension bridge standing firm as storm clouds part to reveal light on the horizon
    August 17, 2026||3.4 min||||

    Upstart Fell on a Riskier Macro. Why Simon Erickson Still Calls It a Strong Buy

    Upstart's own macro index says loan defaults are 60% more likely than average — yet Simon Erickson kept the AI lender a Strong Buy on November 13, 2025. Here's his reasoning.

  • A polished steel lever resting on a small fulcrum lifting a massive granite cube, symbolizing operating leverage
    August 17, 2026||3.6 min||||

    What Is a “Stock Cannibal”? Operating Leverage and Buybacks, Explained

    How can 11% revenue growth turn into 52% earnings growth? Simon Erickson's Paycom review is a live lesson in operating leverage and "stock cannibal" buybacks.

  • Five paths of green light receding into darkness, representing five separate stock verdicts
    August 17, 2026||4.7 min||||

    5 Stocks Simon Erickson Reviewed: 2 Strong Buys and 3 Buys

    Paycom, Upstart, DLocal, TransMedics, MercadoLibre — Simon Erickson updated his conviction rating on all five in 7investing's November 13, 2025 subscriber call. The scorecard, with his reasoning.

  • A sterile pharmacy compounding bench at night with stainless mixing vessels and glass vials under a single clinical light
    August 17, 2026||6.3 min||||

    What Is a Compounded GLP-1 Drug — and Why Was It Legal?

    Compounded semaglutide sold for a quarter of the branded price. Here is the FDA shortage rule that allowed it, and why that window has now closed.

  • An antique brass balance scale with an injectable pen on one pan and an oral tablet on the other, the pans nearly level
    August 17, 2026||6.9 min||||

    Novo Nordisk vs. Hims & Hers: Which GLP-1 Stock Is the Better Buy?

    After the March 2026 truce, Simon Erickson says he is comfortable with either GLP-1 stock. Here is the case for each and the risks on both sides.

  • Two identical medicine vials at opposite ends of a long polished boardroom table with a freshly signed document between them
    August 7, 2026||6.3 min||||

    Novo Nordisk and Hims & Hers Just Called a Truce. What Changed?

    Novo dropped its patent suit and will let Hims & Hers sell Wegovy on its platform. Here is what happened, why it took four years, and what it means.

  • A dark museum corridor lined with glass archive cases holding scientific artifacts, only the nearest one lit from within
    August 17, 2026||5.8 min||||

    3 Years of Breakthrough Technologies: Which Ones Made Investors Money?

    Simon Erickson revisited MIT's 2023, 2024 and 2025 breakthrough lists to see which technologies became businesses. The pattern is a usable framework.